Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1177320120150020099
Korean Journal of Schizophrenia Research
2012 Volume.15 No. 2 p.99 ~ p.105
Psychomotor Performance Relevant to Driving Ability in Patients with Schizophrenia Treated with Haloperidol and Aripiprazole
Han Ji-Hyun

Park Se-Jin
Lee Jong-Il
Chang An-Gi
Kang Shi-Hyun
Soh Min-Ah
Lee Kyung-Jin
Koh Eun-Sang
Roh Sung-Won
Abstract
Objectives: This study aimed to compare psychomotor performance related with automobile driving in patients with schizophrenia under the treatment of a typical antipsychotic agent, haloperidol, or an atypical antipsychotic agent, aripiprazole.

Methods: We evaluated driving ability of schizophrenia patients by using the cognitive perceptual assessment for driving (CPAD). Twelve patients receiving haloperidol monotherapy and 18 taking aripiprazole monotherapy participated in this study and the results of CPAD were compared with each other.

Results: Of 30 participants, 15 (50%) of the patients passed the CPAD to be regarded as competent to drive, 3 (10%) of the patients failed the CPAD considered to be severely impaired. Controlling for sex, age, education, duration of illness, there were no significant differences in the CPAD results between two treatment groups. We observed a trend that patients who received aripiprazole showed a higher total score of the CPAD than haloperidol-treated patients (55.2¡¾4.9 vs. 45.7¡¾8.4, p=0.080).

Conclusion: There were no significant differences in the psychomotor performance relevant to driving ability between haloperidol and aripiprazole groups. But our results suggest that aripiprazole might have the neurocognitive advantage over haloperidol. Future study with a large sample size and diverse antipsychotics is warranted.
KEYWORD
Schizophrenia, Haloperidol, Aripiprazole, Driving, Psychomotor performance
FullTexts / Linksout information
Listed journal information